<DOC>
	<DOCNO>NCT01752491</DOCNO>
	<brief_summary>This phase 1 ( first man ) study test safety add high dose ascorbate ( vitamin C ) standard radiation chemotherapy initial treatment glioblastoma multiforme ( GBM ) .</brief_summary>
	<brief_title>A Phase I Trial High-Dose Ascorbate Glioblastoma Multiforme</brief_title>
	<detailed_description>This phase 1 study test safety add high dose ascorbate ( vitamin C ) standard chemoradiation , radiation complete , 6 cycle temozolomide . Standard treatment glioblastoma multiforme ( GBM ) involve surgery follow radiation combine temozolomide ( chemotherapy ) . After radiation , patient receive cycle temozolomide ( adjuvant chemotherapy ) Participants : - receive high dos intravenous ( IV ) ascorbate three time week chemoradiation - receive high dos intravenous ( IV ) ascorbate twice week adjuvant chemotherapy ( radiation ) This phase 1 study evaluate side effect add drug standard therapy . The dose give participant determine well participant tolerate drug .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must newly diagnose ( i.e. , within 5 week ) , histologically cytologically confirm glioblastoma multiforme . Diagnosis must make surgical biopsy excision . Therapy must begin ≤ 5 week surgery . Age ≥ 18 year ECOG performance status 02 ( Karnofsky &gt; 50 % ) . A complete blood count differential must obtain within 21 day prior first dose radiation , adequate bone marrow function define : Absolute neutrophil count ( ANC ) ≥ 1500 cell per mm3 Platelets ≥ 100,000 per mm3 Hemoglobin ≥ 8 g/dL Serum blood chemistry within 21 day first day radiation , define : Creatinine ≤ 2.0 mg Total bilirubin ≤ 1.5 mg/dL ALT ( Alanine Aminotransferase ) ≤ 3 time institutional upper limit normal AST ( Aspartate Aminotransferase ) ≤ 3 time institutional upper limit normal Tolerate one text dose ( 15g ) ascorbate Not pregnant Ability understand willingness sign write informed consent document Recurrent high grade glioma G6PD ( glucose6phosphate dehydrogenase ) deficiency Patients actively receive insulin unless approve study medical monitor , study sponsor , study principal investigator . History allergic reaction attribute compound similar chemical biologic composition temozolomide . Significant comorbid central nervous system disease , include limited , multiple sclerosis . Patients follow drug drug substitution : flecainide , methadone , amphetamine , quinidine , chlorpropamide . High dose ascorbic acid may affect urine acidification , result , may affect clearance rate drug . Prior invasive malignancy ( except nonmelanomatous skin cancer carcinoma situ cervix bladder ) unless disease free ≥ 5 year . Patients receive prior chemotherapy ( include Gliadel wafer ) current glioma . Prior radiation therapy head neck , would result overlap radiation therapy field . Patients may receive investigational agent . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study ionize radiation know teratogen , temozolomide Class D agent potential teratogenic abortifacient effect . Known HIVpositive individual . Highdose ascorbate acid know CYP450 3A4 ( enzyme pathway ) inducer , result low serum level antiretroviral drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ascorbate</keyword>
	<keyword>Ascorbic acid</keyword>
	<keyword>Vitamin C</keyword>
	<keyword>Radiation</keyword>
	<keyword>Temozolomide</keyword>
</DOC>